AIDS Treatment News logo      

July 23, 2010

Second-ever pre-exposure prophylaxis study reports no safety concerns and promising result "The last day of the Vienna International AIDS Conference featured the results of the second-ever completed randomised controlled trial of pre-exposure prophylaxis (PrEP) – giving antiretrovirals to HIV-negative people at high risk of HIV to prevent them becoming infected.

"The trial, which randomised 400 gay men to take either a daily tenofovir (Viread) or a daily placebo pill, was too small to serve as an efficacy trial.

"Lisa Grohskopf of the US Centers for Disease Control (CDC) told the conference that none of the seven men who became infected with HIV during the trial was taking tenofovir but, because of the size of the trial, this could possibly be a random effect – nothing could be read into it about the efficacy of once-daily tenofovir as a means of preventing HIV."